Cure8 research brief
These Day 1 scores aim to identify patients unlikely to respond to IV steroids so treatment can be escalated earlier; that could shorten delays to rescue therapy and potentially improve outcomes for people admitted with acute severe UC.
Clinicians managing hospitalized ASUC patients, gastroenterologists, IBD teams, and researchers studying prognostic tools; informed adult patients and caregivers may also find the information relevant.
This multicenter retrospective validation compared three Day 1 prognostic scores (ADMIT-ASC, ACE, ROR) for predicting steroid non-response in adults hospitalized with acute severe ulcerative colitis (ASUC).
In 238 patients across three Australian centers (2018–2023), all scores showed moderate discrimination; the ROR score had the highest AUROC (0.72) while ADMIT-ASC and ACE were 0.68 and 0.66. At published thresholds, ADMIT-ASC and ACE were more specific but less sensitive; ROR traded specificity for greater sensitivity.
Performance was similar in biologic-naive and biologic-exposed subgroups.
This report is a multicenter retrospective validation (abstract-level summary). The scores showed only moderate accuracy and different trade-offs between sensitivity and specificity; results should be interpreted alongside clinical assessment. The abstract does not provide detailed calibration data or patient-level decision thresholds beyond cited published cutoffs.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A non-invasive MRI method that correlates with histology and endoscopic scores could reduce the need for frequent colonoscopy for assessing IBD activity and help monitor treatment response, especially when endoscopy is...
Faecal calprotectin appears to be the best non‑invasive test among those studied for distinguishing UC from Crohn’s disease and for reflecting mucosal inflammation. Simpler blood‑based scores may help gauge systemic...
Simple, routinely measured nutritional scores were associated with early (14-week) remission on vedolizumab in patients with moderate-to-severe UC, which could help identify patients more likely to respond early to this...
